Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20
Background and Aims: The purpose of this retrospective study is to describe the Graves’ hyperthyroidism patients with severe liver injury treated by iodine-131 combined with plasma exchange (PE). Methods: The patients who had hyperthyroidism caused by Graves’ disease, with severe liver injury (The l...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572324001961 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199258738884608 |
|---|---|
| author | Xin-Fang Zhu Rong-Rong Ding Bing-Yao Wang Yun-hui Yang Fu-Xia Ta Yuan Wang Qing-Mei Gao Qi Zhang Rong Xia Xing-Guang Luo Xuan Wang Jian-Ming Zheng Hui-Qing Zhu |
| author_facet | Xin-Fang Zhu Rong-Rong Ding Bing-Yao Wang Yun-hui Yang Fu-Xia Ta Yuan Wang Qing-Mei Gao Qi Zhang Rong Xia Xing-Guang Luo Xuan Wang Jian-Ming Zheng Hui-Qing Zhu |
| author_sort | Xin-Fang Zhu |
| collection | DOAJ |
| description | Background and Aims: The purpose of this retrospective study is to describe the Graves’ hyperthyroidism patients with severe liver injury treated by iodine-131 combined with plasma exchange (PE). Methods: The patients who had hyperthyroidism caused by Graves’ disease, with severe liver injury (The level of total bilirubin ≥12 mg/dL), and after 1 week of liver protective medication treatment, the patient’s liver function did not improve, were enrolled in this study. All patients were treated with iodine-131 and PE. The patients’ laboratory data after 3 months of isotope therapy were collected. Results: In this study, there were 8 patients included, the average model for end-stage liver disease (MELD) scores were greater than 20 (ranges from 19 to 30) at baseline. The levels of hemoglobin, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, glutamyl transpeptidase, MELD scores, free triiodothyronine, free thyroxine, antithyroid peroxidase autoantibody and serum thyrotropin receptor antibodies after PE treatment were significantly lower than before PE treatment (P < .05). The level of total bilirubin at 3 months post-131I treatment was significantly lower than pre-131I treatment (P = .0200), the same was the level of direct bilirubin (P = .0200). Conclusion: Our study enrolled Graves’ hyperthyroidism patients with severe liver injury whose average MELD scores were greater than 20, and shows that liver function test can recover on about 3 months treated iodine-131 combined with PE therapy. |
| format | Article |
| id | doaj-art-6168cca18fc14148a482649a6a8a0d29 |
| institution | Kabale University |
| issn | 2772-5723 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj-art-6168cca18fc14148a482649a6a8a0d292025-02-08T05:01:41ZengElsevierGastro Hep Advances2772-57232025-01-0144100600Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20Xin-Fang Zhu0Rong-Rong Ding1Bing-Yao Wang2Yun-hui Yang3Fu-Xia Ta4Yuan Wang5Qing-Mei Gao6Qi Zhang7Rong Xia8Xing-Guang Luo9Xuan Wang10Jian-Ming Zheng11Hui-Qing Zhu12Department of Transfusion, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; Liver Diseases Center, Huashan Hospital, Fudan University, Shanghai, China; National Medical Center for Infectious Diseases, Shanghai, China; Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; Liver Diseases Center, Huashan Hospital, Fudan University, Shanghai, China; National Medical Center for Infectious Diseases, Shanghai, China; Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Transfusion, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Transfusion, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Transfusion, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Transfusion, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Genetics, Yale University School of Medicine, New Haven, ConnecticutDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; Liver Diseases Center, Huashan Hospital, Fudan University, Shanghai, China; National Medical Center for Infectious Diseases, Shanghai, China; Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, China; Xuan Wang, Department of Infectious Diseases, Huashan Hospital, Fudan University, No.12 Middle Wulumuqi Road, Shanghai 200040, China.Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; Liver Diseases Center, Huashan Hospital, Fudan University, Shanghai, China; National Medical Center for Infectious Diseases, Shanghai, China; Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Huashan Hospital, Fudan University, Shanghai, China; Jian-Ming Zheng, Department of Infectious Diseases, Huashan Hospital, Fudan University, No.12 Middle Wulumuqi Road, Shanghai 200040, China.Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China; Correspondence: Address correspondence to: Hui-Qing Zhu, Department of Nuclear Medicine, Huashan Hospital, Fudan University, No.12 Middle Wulumuqi Road, Shanghai 200040, China.Background and Aims: The purpose of this retrospective study is to describe the Graves’ hyperthyroidism patients with severe liver injury treated by iodine-131 combined with plasma exchange (PE). Methods: The patients who had hyperthyroidism caused by Graves’ disease, with severe liver injury (The level of total bilirubin ≥12 mg/dL), and after 1 week of liver protective medication treatment, the patient’s liver function did not improve, were enrolled in this study. All patients were treated with iodine-131 and PE. The patients’ laboratory data after 3 months of isotope therapy were collected. Results: In this study, there were 8 patients included, the average model for end-stage liver disease (MELD) scores were greater than 20 (ranges from 19 to 30) at baseline. The levels of hemoglobin, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, glutamyl transpeptidase, MELD scores, free triiodothyronine, free thyroxine, antithyroid peroxidase autoantibody and serum thyrotropin receptor antibodies after PE treatment were significantly lower than before PE treatment (P < .05). The level of total bilirubin at 3 months post-131I treatment was significantly lower than pre-131I treatment (P = .0200), the same was the level of direct bilirubin (P = .0200). Conclusion: Our study enrolled Graves’ hyperthyroidism patients with severe liver injury whose average MELD scores were greater than 20, and shows that liver function test can recover on about 3 months treated iodine-131 combined with PE therapy.http://www.sciencedirect.com/science/article/pii/S2772572324001961Graves’ DiseaseIsotope I131 TherapyPlasma ExchangeLiver Failure |
| spellingShingle | Xin-Fang Zhu Rong-Rong Ding Bing-Yao Wang Yun-hui Yang Fu-Xia Ta Yuan Wang Qing-Mei Gao Qi Zhang Rong Xia Xing-Guang Luo Xuan Wang Jian-Ming Zheng Hui-Qing Zhu Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 Gastro Hep Advances Graves’ Disease Isotope I131 Therapy Plasma Exchange Liver Failure |
| title | Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 |
| title_full | Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 |
| title_fullStr | Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 |
| title_full_unstemmed | Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 |
| title_short | Iodine-131 Combined With Plasma Exchange Treatment in Graves’ Hyperthyroidism Patients With Severe Liver Injury Whose Average Model for End-Stage Liver Disease Scores >20 |
| title_sort | iodine 131 combined with plasma exchange treatment in graves hyperthyroidism patients with severe liver injury whose average model for end stage liver disease scores 20 |
| topic | Graves’ Disease Isotope I131 Therapy Plasma Exchange Liver Failure |
| url | http://www.sciencedirect.com/science/article/pii/S2772572324001961 |
| work_keys_str_mv | AT xinfangzhu iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT rongrongding iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT bingyaowang iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT yunhuiyang iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT fuxiata iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT yuanwang iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT qingmeigao iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT qizhang iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT rongxia iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT xingguangluo iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT xuanwang iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT jianmingzheng iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 AT huiqingzhu iodine131combinedwithplasmaexchangetreatmentingraveshyperthyroidismpatientswithsevereliverinjurywhoseaveragemodelforendstageliverdiseasescores20 |